Ultragenyx Pharmaceutical Inc.
RARE · Nasdaq · United States
Share price · RARE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RARE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Sep 2026-44.0%
- Day beforeOther material event
- 30 Jun 2026+8.8%
Nothing announced by RARE that day or the session before.
- 17 Jun 2026+8.3%
Nothing announced by RARE that day or the session before.
- 19 May 2026-7.2%
Nothing announced by RARE that day or the session before.
- 30 Dec 2025+15.5%
- Day beforeMereo BioPharma: Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143)MREO +30.2%
- 29 Dec 2025-42.3%
- Mereo BioPharma: Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143)MREO -87.7%
- 16 Dec 2025-5.2%
Nothing announced by RARE that day or the session before.
Share of unusual movement by asset
For each asset, the share of RARE's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
setrusumabevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 35% |
| Other company news (earnings, financing, releases naming no asset) | — | 36% |
| Sessions with no dated event | — | 29% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Evinacumab(Evkeeza) | Approved | ANGPTL3Monoclonal antibody | Homozygous Familial Hypercholesterolemia |
| Phase 3 | SclerostinMonoclonal antibody | Osteogenesis Imperfecta |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $173M | $154M | $150M+ $116M short-term inv. | $118M-$43M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $214M | $167M | $125M+ $167M short-term inv. | $92M-$97M operating cash flow | report ↗ |
| 2026-Q1 | $136M | $187M | $175M+ $238M short-term inv. | $185M-$197M operating cash flow | report ↗ |
| 2025-Q3 | $160M | $216M | $203M+ $223M short-term inv. | $180M-$91M operating cash flow | report ↗ |
| 2025-Q2 | $167M | $165M | $176M+ $311M short-term inv. | $115M-$108M operating cash flow | report ↗ |
| 2025-Q1 | $139M | $166M | $127M+ $367M short-term inv. | $151M-$166M operating cash flow | report ↗ |
| 2024-Q3 | $139M | $170M | $151M+ $471M short-term inv. | $134M-$67M operating cash flow | report ↗ |
| 2024-Q2 | $147M | $162M | $481M+ $283M short-term inv. | $132M-$77M operating cash flow | report ↗ |
| 2024-Q1 | $109M | $178M | $112M+ $300M short-term inv. | $171M-$191M operating cash flow | report ↗ |
| 2023-Q3 | $98M | $157M | $73M+ $370M short-term inv. | $160M-$118M operating cash flow | report ↗ |
| 2023-Q2 | $108M | $165M | $102M+ $450M short-term inv. | $160M-$116M operating cash flow | report ↗ |
| 2023-Q1 | $101M | $166M | $86M+ $544M short-term inv. | $164M-$157M operating cash flow | report ↗ |
| 2022-Q3 | $91M | $237M | $392M+ $497M short-term inv. | $245M-$95M operating cash flow | report ↗ |
| 2022-Q2 | $89M | $155M | $160M+ $383M short-term inv. | $158M-$77M operating cash flow | report ↗ |
| 2022-Q1 | $80M | $143M | $154M+ $444M short-term inv. | $152M-$118M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $673M | $750M | $421M+ $259M short-term inv. | $144M-$466M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $560M | $698M | $174M+ $436M short-term inv. | $142M-$414M operating cash flow | report ↗ |
| 2023-FY | $434M | $648M | $214M+ $364M short-term inv. | $152M-$475M operating cash flow | report ↗ |
| 2022-FY | $363M | $706M | $133M+ $615M short-term inv. | $177M-$380M operating cash flow | report ↗ |
| 2021-FY | $351M | $497M | $308M+ $433M short-term inv. | $114M-$339M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 28 sales ($3.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-15 | Horn Howard · Chief Financial Officer | Open-market sale | 7,066 | $15.27 | $108K | Form 4 |
| 2026-09-15 | Huizenga Theodore Alan · SVP, Chief Accounting Officer | Open-market sale | 1,283 | $13.57 | $17K | Form 4 |
| 2026-09-03 | Huizenga Theodore Alan · SVP, Chief Accounting Officer | Open-market sale | 161 | $13.99 | $2K | Form 4 |
| 2026-08-03 | Horn Howard · Chief Financial Officer | Open-market sale | 4,696 | $24.92 | $117K | Form 4 |
| 2026-08-03 | Parschauer Karah Herdman · EVP and Chief Legal Officer | Open-market sale | 1,900 | $24.92 | $47K | Form 4 |
| 2026-07-01 | Horn Howard · Chief Financial Officer | Open-market sale | 4,698 | $33.13 | $156K | Form 4 |
| 2026-06-15 | Parschauer Karah Herdman · EVP and Chief Legal Officer | Open-market sale | 1,899 | $24.62 | $47K | Form 4 |
| 2026-06-15 | Sanders Corazon (Corsee) D. · director | Open-market sale | 2,000 | $25.05 | $50K | Form 4 |